Severity
Low
FDA Drug recall · Reported February 15, 2017
Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.
Aurobindo Pharma USA Inc recalled Pantoprazole Sodium for Injection, 40mg per vial, Single-dose vial, Rx only, Mfd. in In… - a low-severity action.
Pantoprazole Sodium for Injection, 40mg per vial, Single-dose vial, Rx only, Mfd. in In… was recalled by Aurobindo Pharma USA Inc in February 15, 2017. Reason: Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.. Check the official notice for the remedy. Verify recall #D-0470-2017 with the FDA Drug before acting.
The recall
Aurobindo Pharma USA Inc issued this low-severity FDA Drug recall-Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance..
Sourced from official FDA Drug enforcement records. Verify recall #D-0470-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0470-2017) was formally reported on February 15, 2017, with the manufacturer initiating the action on December 16, 2016. It is classified under Low severity (Class III), with a current status of Terminated. Aurobindo Pharma USA Inc is listed as the recalling firm, operating out of Plainsboro, NJ. Federal records list the affected scope as 29800 vials.
The documented reason for this recall is: Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance. Distribution data in the federal record shows the product reached: Nationwide in US. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
29800 vials
Related Recalls
6
5 from same agency
Pantoprazole Sodium for Injection, 40mg per vial, Single-dose vial, Rx only, Mfd. in India for: Auromedics Pharma LLC 6 Wheeling Road, Dayton, NJ 08810, NDC 55150-202-00
Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0470-2017 |
| Date reported | February 15, 2017 |
| Date initiated | December 16, 2016 |
| Recalling firm | Aurobindo Pharma USA Inc |
| Firm location | Plainsboro, NJ |
| Affected scope | 29800 vials |
| Distribution | Nationwide in US |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 15, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.